Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Relapsed/Refractory Multiple Myeloma Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FCRL5/CD307e drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCRL5/CD307e ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View FCRL5 Products |
| Gene Delivery | FCRL5/CD307e Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and flow cytometry assays. |
View FCRL5 Products |
| Benchmark Ab | Anti-FCRL5 Recombinant Antibody (Cevostamab Sequence) Recombinant positive control for binding and T-cell activation assays. |
View FCRL5 Products |
| Validator | FCRL5/CD307e siRNA Set For target knockdown verification and specificity profiling. |
View FCRL5 Products |
| Related Target A | CD3 epsilon (CD3e) Crucial co-target for T-cell engaging bispecific antibodies (TCBs). |
View CD3 Products |
| Related Target B | BCMA (TNFRSF17) Primary plasma cell target; used for sequential therapy and combination screening. |
View BCMA Products |
| Related Target C | GPRC5D Orphan GPCR target in multiple myeloma; key for multi-specific and resistance bypass assays. |
View GPRC5D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Epitope mapping (Domain 9 specificity) | Truncated and domain-specific recombinant FCRL5 proteins available. |
| Cross-species cyno/mouse evaluation | Human, Cynomolgus, and Mouse ortholog proteins strictly verified by Mass Spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (Cevostamab biosimilar) included. |
| False Positives in Flow Cytometry | High-titer Lentivirus for stable cell line generation to verify native conformation. |
Live FCRL5/CD307e R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FCRL5/CD307e therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to T-cell engaging bispecific antibodies (TCBs) and antibody-drug conjugates (ADCs). FCRL5 is a highly restricted B-cell lineage marker overexpressed in multiple myeloma (MM) plasma cells, making it an ideal target for immunotherapy. As first-generation BCMA-targeted therapies face resistance due to antigen loss, the next wave of R&D is targeting FCRL5 as a non-overlapping alternative or combination partner.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibody (TCB) | Roche (Cevostamab) | Relapsed/Refractory Multiple Myeloma (RRMM) | T-cell synapse validation (Requires high-purity CD3e and FCRL5 ECD-Fc proteins) |
| Antibody-Drug Conjugate (ADC) | Genentech (DFRF4539A - historical) | Multiple Myeloma, B-cell Malignancies | Internalization assay (Requires native glycosylated FCRL5 target protein) |
| CAR-T Therapy | Academic Institutions, Biotech Startups | Advanced Plasma Cell Malignancies | Target density and specificity screening (Requires Lentivirus for stable cell line construction) |